Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas
| Autor: | Christoph Aderhold, Anne Lammert, Richard Birk, Karl Hörmann, Clemens Hock, Beatrice Kuhlin, Johannes David Schultz, Benedikt Kramer |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Dasatinib Antineoplastic Agents 03 medical and health sciences Erlotinib Hydrochloride 0302 clinical medicine Gefitinib Antigens CD Internal medicine Cell Line Tumor medicine Humans neoplasms Protein Kinase Inhibitors beta Catenin Human papillomavirus 16 business.industry General Medicine medicine.disease Cadherins Head and neck squamous-cell carcinoma 030104 developmental biology Pyrimidines Nilotinib Head and Neck Neoplasms 030220 oncology & carcinogenesis Catenin Carcinoma Squamous Cell Quinazolines Erlotinib business Tyrosine kinase medicine.drug |
| Zdroj: | Anticancer research. 37(6) |
| ISSN: | 1791-7530 |
| Popis: | Background: The validation of potential molecular targets in head and neck squamous cell carcinoma (SCC) is mandatory. β-Catenin and E-cadherin are crucial for cancer progression through epithelial–mesenchymal transition. We analyzed the effect of the tyrosine kinase inhibitors nilotinib, dasatinib, erlotinib and gefitinib on β-catenin and E-cadherin expression in SCC with respect to human papillomavirus (HPV) status. Materials and Methods: Expression of β-catenin and E-cadherin in cell lines UMSCC 11A, UMSCC 14C and CERV196 under the influence of tyrosine kinase inhibitors were analyzed by enzyme-linked immunosorbent assay. Results: All agents reduced β-catenin and E-cadherin expression of HPV16-negative cells. Increased E-cadherin expression was observed after treatment with gefitinib and dasatinib in HPV16-positive cells. Conclusion: All substances, nilotinib, dasatinib, erlotinib and gefitinib have a significant impact on β-catenin and E-cadherin expression in both HPV16-positive and HPV16-negative cells in vitro. Alterations of β-catenin and E-cadherin could provide novel insights for future targeted therapies of head and neck SCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|